Formulation

The Access to Advanced Health Institute Receives up to $12.7 Million to Develop Novel NanoAlum Adjuvant Formulation for Better Protection Against Tuberculosis and Pandemic Influenza

Retrieved on: 
Thursday, March 7, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240307661956/en/
    This five-year prototype project will support AAHI’s development and optimization of “NanoAlum” – a novel nanoparticle adjuvant formulation, made from aluminum salts (“alum”).
  • Alum-adjuvanted vaccines have been less effective against diseases such as tuberculosis and influenza, which are more complex to target and can be challenging to manufacture because they require special sterilization methods.
  • AAHI’s NanoAlum formulation changes the size, shape, and charge of alum particles to enhance specific immune responses for better vaccine protection against complex diseases.
  • AAHI’s prototype project for MCDC will pair the combined 3M-052 and NanoAlum formulation with tuberculosis and pandemic influenza vaccine antigens.

2024 Feather in Her Cap and High Flyer Award Winners Named for Outstanding Achievements in Animal Health Industry

Retrieved on: 
Tuesday, January 16, 2024

The Feather in Her Cap Association, Inc. and 300 industry leaders honored 11 women for their outstanding career achievements in Animal Health at the seventh annual Feather in Her Cap awards ceremony.

Key Points: 
  • The Feather in Her Cap Association, Inc. and 300 industry leaders honored 11 women for their outstanding career achievements in Animal Health at the seventh annual Feather in Her Cap awards ceremony.
  • Andrea J. Gonzales Ph.D., vice president of Global Companion Animal Therapeutics at Zoetis, Inc., (NYSE: ZTS) was awarded the 2024 Feather in Her Cap award and Katharina Bohnenblust Ph.D., senior director, head of Formulation Development at Elanco Animal Health (NYSE: ELAN) was this year’s recipient of the 2024 High Flyer award.
  • Each year, the Feather in Her Cap award winner chooses an animal-related non-profit organization to receive a $5,000 donation.
  • The nomination process will reopen in Q3 of 2024 to celebrate more outstanding women in Animal Health in 2025.

China Pharmaceutical Competitive Landscape and Drugs Pipeline Analysis Report 2023: Business Overview of 330 Companies, 1500 Drugs in Trials, & 200 Commercially Approved Drugs - ResearchAndMarkets.com

Retrieved on: 
Friday, November 3, 2023

The "China Pharmaceutical Companies and Drugs Pipeline Insight 2023" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Pharmaceutical Companies and Drugs Pipeline Insight 2023" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • For as long as anybody can remember, the US has been the largest pharmaceutical market globally.
  • The Chinese pharmaceutical market is dynamic, with numerous unanticipated potential for future expansion, making it an ideal market to explore.
  • Chinese Pharmaceuticals Companies Business Overview Insight: 330 Companies
    Comprehensive Insight On Drugs In Clinical Trials By Companies: > 1500 Drugs
    Clinical Trials Insight By Companies, Indication, Formulation and Phase
    Comprehensive Insight On Drugs Commercially Approved In Market: > 200 Drugs

Global Agricultural Adjuvants Market to Reach $5.25 Billion by 2030, Driven by Increasing Crop Protection Needs Amidst Shrinking Arable Land - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 1, 2023

The global agricultural adjuvants market size is expected to reach USD 5.25 billion by 2030, registering a CAGR of 4.7% from 2023 to 2030.

Key Points: 
  • The global agricultural adjuvants market size is expected to reach USD 5.25 billion by 2030, registering a CAGR of 4.7% from 2023 to 2030.
  • Industry growth is majorly driven by the increasing demand for crop protection chemicals for improving the yield of crops due to shrinking arable land and growing population globally.
  • The global demand for crop protection products is expected to drive market growth.
  • This has resulted in the growing demand for agrochemicals, which, in turn, will drive the demand for the product market.

FORMULATED MATERIALS INTRODUCES THE REVOLUTIONARY ELEVATION ONE WATERPROOFING SYSTEM - An Unbeatable Solution for Elevated Wood Balconies

Retrieved on: 
Friday, September 29, 2023

OKLAHOMA CITY, Sept. 29, 2023 /PRNewswire/ -- Formulated Materials®, a leading innovator in construction materials, proudly introduces the ELEVATION WATERPROOFING SYSTEM™, a holistic solution for waterproofing elevated wood balconies.

Key Points: 
  • OKLAHOMA CITY, Sept. 29, 2023 /PRNewswire/ -- Formulated Materials®, a leading innovator in construction materials, proudly introduces the ELEVATION WATERPROOFING SYSTEM™, a holistic solution for waterproofing elevated wood balconies.
  • This revolutionary system promises to eradicate the familiar challenges that lead to waterproofing failures, ensuring utmost reliability.
  • The ELEVATION Balcony Waterproofing System by Formulated Materials offers multiple benefits that set it apart in the industry.
  • Reach out to Formulated Materials to explore the transformative potential of the ELEVATION WATERPROOFING SYSTEM for your balconies.

Dotmatics Releases New Chemicals & Materials Solution Focused on Data-Driven Research to Accelerate Product Development

Retrieved on: 
Wednesday, September 27, 2023

BOSTON, Sept. 27, 2023 /PRNewswire/ -- Dotmatics, a leader in R&D scientific software connecting science, data, and decision-making, today announced its new Dotmatics Chemicals & Materials Solution specifically designed to help R&D leaders get more insight from their data, faster. With its focus on simplifying data intelligence, the new Dotmatics Chemicals & Materials Solution helps researchers accelerate new product development by enabling data-driven research, simplifying project management, and reducing the complexities of research IT infrastructure. Learn more at: https://www.dotmatics.com/solutions/chemicals-materials-science-software.

Key Points: 
  • With its focus on simplifying data intelligence, the new Dotmatics Chemicals & Materials Solution helps researchers accelerate new product development by enabling data-driven research, simplifying project management, and reducing the complexities of research IT infrastructure.
  • "We are bringing the Dotmatics Chemicals & Materials solution to market specifically to empower teams to gain insights, make informed decisions, and streamline workflows, ultimately driving greater efficiency and productivity."
  • The Dotmatics Chemicals & Materials Solution includes the following workflows and capabilities:
    Ingredient Management: Leverages Dotmatics Bioregister as a general entity registration framework to define and track ingredient properties.
  • The Dotmatics Chemicals & Materials Solution is now generally available to help researchers accelerate new product development.

Global Formulation Development Outsourcing Market Poised for Substantial Growth from 2023 to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 5, 2023

The Formulation Development Outsourcing Market is projected to experience substantial growth during the forecast period from 2023 to 2028.

Key Points: 
  • The Formulation Development Outsourcing Market is projected to experience substantial growth during the forecast period from 2023 to 2028.
  • Cost Savings: One of the primary drivers of growth in the Global Formulation Development Outsourcing Market is cost savings.
  • Increased Complexity of Drug Development: The complexity of drug development is driving the growth of the Formulation Development Outsourcing Market.
  • The comprehensive Global Formulation Development Outsourcing Market report covers market segmentation by product and service, application, and end-use, providing valuable insights into the market's current state and future prospects.

Mineral Supplements Market Trends Analysis Report 2023-2030: Growing Demand Driven by Rising Incidences of Chronic Diseases Worldwide - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 29, 2023

The major factor influencing the industry growth is the growing worldwide incidences of chronic diseases such as anemia, osteoporosis, cancer, and diabetes is boosting the growth as these supplements are useful for managing such conditions.

Key Points: 
  • The major factor influencing the industry growth is the growing worldwide incidences of chronic diseases such as anemia, osteoporosis, cancer, and diabetes is boosting the growth as these supplements are useful for managing such conditions.
  • Furthermore, an increasing percentage of working- and middle-class people, along with growing disposable income, is projected to boost demand in the coming years.
  • Growing consumer preference for preventive healthcare is also one of the key factors augmenting the product demand.
  • Increasing awareness about the benefits of nutrient supplementation among consumers is further expected to fuel the demand for mineral supplements.

Astria Therapeutics Names John Ruesch as Senior Vice President, Pharmaceutical Sciences and Technical Operations

Retrieved on: 
Monday, July 17, 2023

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it has named John Ruesch as Senior Vice President, Pharmaceutical Sciences and Technical Operations.

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it has named John Ruesch as Senior Vice President, Pharmaceutical Sciences and Technical Operations.
  • Mr. Ruesch brings to Astria more than 25 years of experience in pharmaceutical drug development.
  • “We are pleased to have John’s leadership and experience as we progress STAR-0215 through clinical development,” said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics.
  • Prior to that, he held several roles at Biogen, Inc., including Vice President, Protein Technical Development, Senior Director, Head of Protein Technical Development, and Senior Director, Drug Product Development.

Global Intravenous Solutions Market Report 2023: Players Include ICU Medical, JW Life Science, Otsuka Pharmaceutical and Pfizer - ResearchAndMarkets.com

Retrieved on: 
Monday, June 12, 2023

Ltd.

Key Points: 
  • Ltd.
    Intravenous solutions present a combination of nutrients that support patients to get essential nutrition.
  • The demand for intravenous solutions on the global front is undergoing steady growth and its market presents a higher growth in the Asia-Pacific region.
  • The intravenous solutions manufacturers and vendors worldwide are perpetually improving the nature of products, and sales and distribution methods respectively.
  • Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2031.